SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 63749
  • 2
    Koelbl H, Mostwin J, Boiteux JP et al. Pathophysiology. In AbramsP, CardozoL, KhouryS, WeinA eds, Incontinence, 2nd International Consultation on Incontinence, 2nd edn., Chapt. 4. Plymouth: Plymbridge Distrubutors, UK, 2002: 20341
  • 3
    Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology 2003; 62 (Suppl. 2): 2837
  • 4
    Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 7606
  • 5
    Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 32736
  • 6
    Chai TC, Belville WD, McGuire EJ, Nyquist L. Specificity of the American Urological Association voiding symptom index: comparison of unselected and selected samples of both sexes. J Urol 1993; 150: 17103
  • 7
    Schatzl G, Temml C, Waldmuller J, Thurridl T, Haidinger G, Madersbacher S. A comparative cross-sectional study of lower urinary tract symptoms in both sexes. Eur Urol 2001; 40: 2139
  • 8
    Price DA, Ramsden PD, Stobbart D. The unstable bladder and prostatectomy. Br J Urol 1980; 52: 52931
  • 9
    Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005; 48: 526
  • 10
    Hay-Smith J, Herbison P, Ellis G, Moore K. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2002; 3: CD003781
  • 11
    AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003; 170: 53047
  • 12
    Anonymous. British National Formulary 51. March 2006 edition. London: Pharmaceutical Press, 2006
  • 13
    Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol 2002; 31: 1503
  • 14
    Khan KS, Ter Riet G, Popay J, Nixon J, Kleijnen J. Study quality assessment. In KhanKS, Ter RietG, GlanvilleJ, SowdenAJ, KleijnenJ eds, Undertaking Systematic Reviews of Research on Effectiveness, 2nd edn, CRD Report Number 4, Chapt. 5. York: York Publishing Services Ltd., 2001.
  • 15
    Lukkarinen O, Grohn P, Wilen-Rosenqvist G, Juusela H, Sotarauta M, Lehtonen T. A controlled, double-blind, cross-over study of terodiline in motor urge incontinence. Ann Chir Gynaecol 1987; 76: 12832
  • 16
    Tsujimoto Y, Fujisue H, Shima H et al. [Clinical evaluation of long-term administration of terodiline hydrochloride for the treatment of patients with pollakisuria and incontinence]. Hinyokika Kiyo 1988; 34: 72432
  • 17
    Voss HE, Griboff SI, Gelfand MI. Relation of the antispasmodic anisotropine methylbromide to parasympathetic control of the male urinary tract. Curr Ther Res Clin Exp 1966; 8: 1879
  • 18
    Fujiwara E, Nakano H, Nihira H et al. [Clinical effects of terodiline hydrochloride for urinary frequency and sense of residual urine]. Hinyokika Kiyo 1988; 34: 7338
  • 19
    Lee KS, Kim DY, Kim JC et al. Combination treatment with propiverine hydrochloride plus doxazosin GITS in men with overactive bladder coexisting benign prostatic obstruction: a prospective, randomized, controlled, multicenter study. Proceedings of the International Continence Society 2004: 34th Annual Meeting with the International UroGynecological Association Paris, France 2004: Abstract 207
  • 20
    Kaplan SA, Walmsley K, Te AE. Use of muscarinic receptor antagonists as monotherapy in men with lower urinary tract symptoms who failed previous therapy with alpha blockers (Abstract AUA Annual Meeting). J Urol 2004; 171 (Suppl.): Abstract 917
  • 21
    Lee JY, Jung JH, Ko JS. Identifying patients with benign prostatic hyperplasia with overactive bladder and determining the efficacy of combination therapy with alpha blocker and tolterodine. J Urol 2003; 169 (Suppl.): 477, Abstract 1788
  • 22
    Okada H, Shirakawa T, Sengoku A et al. Propiverine hydrochloride relieves irritative symptoms of benign prostatic hyperplasia. Proceedings of the International Continence Society 2003: 33rd Annual Meeting, Florence, Italy. Abstract 508
  • 23
    Abrams P, Hussain I. Safety and tolerability of tolterodine in men with bladder outlet obstruction and symptomatic detrusor overactivity. Progrès En Urologie 2005; 15 (Suppl. 2): 29, Abstract
  • 24
    Abrams P. Tolterodine therapy in men with bladder outlet obstruction and symptomatic detrusor overactivity is not associated with urinary safety concerns. J Urol 2002; 167 (Suppl.): 1048, Abstract
  • 25
    Abrams P, Kaplan S, Millard R. Safety of tolterodine in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity. Eur Urol Suppl 2002; 1: 132
  • 26
    Abrams P, Kaplan S, Millard R. Tolterodine treatment is safe in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity (DO). Neurourol Urodyn 2001; 20: 5478 (Abstract)
  • 27
    Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis I, Perimenis P, Barbalias G. Combination treatment with an α-blocker plus an anticholinergic improves quality of life in patients with bladder outlet obstruction. A prospective, randomized, controlled study. Neurourol Urodyn 2002; 21: 3089 (Abstract)
  • 28
    Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006; 175: 9991004
  • 29
    Lee KS, Choo MS, Kim DY et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005; 174: 13348
  • 30
    Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003; 169: 22536
  • 31
    Saitoh H, Yamada T, Oshima H et al. A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and/or urinary incontinence. Jap J Urol Surg 1999; 12: 52536
  • 32
    Dahm TL, Ostri P, Kristensen JK et al. Flavoxate treatment of micturition disorders accompanying benign prostatic hypertrophy: a double-blind placebo-controlled multicenter investigation. Urol Int 1995; 55: 2058
  • 33
    Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005; 174: 22736
  • 34
    Lee JY, Byun S, Kim JH, Lee DH. Initial α-blocker and anticholinergic combined treatment in overactive bladder/benign prostatic obstruction (OAB/BPO) patients. Progrès En Urologie 2005; 15 (Suppl 2): 25 (Abstract
  • 35
    Lim E, Chia SJ. Combination therapy using alpha-blocker and antimuscarinic drugs in men with lower urinary tract symptoms suggestive of bladder outlet obstruction and an overactive bladder: is it safe and efficacious?. Proceedings of the International Continence Society 2005: 35th Annual Meeting, Montréal, Canada. Abstract 205
  • 36
    Sugiyama T, Shimizu N, Hashimoto K et al. [Pharmacological evaluation of efficacy and safety of propiverine hydrochloride in patients of overactive bladder: Relationship between urodynamic observation and propiverine pharmacokinetics]. Nippon Hinyokika Gakkai Zasshi 2005; 96: 6707
  • 37
    Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004; 94: 81720
  • 38
    Sugiyama T, Shimizu N, Yoshioka N, Hanai A, Matsumoto S, Uemura H. The treatment of overactive bladder symptoms related to benign prostatic hyperplasia with an anticholinergic agent. NBS (J Jap Neurogenic Bladder Society) 2004; 15: 1917
  • 39
    Okada H, Shirakawa T, Muto S et al. Propiverine hydrochloride relieves irritative symptoms of benign prostatic hyperplasia. J Urol 2004; 171 (Suppl.): 3578, Abstract
  • 40
    Suzuki Y, Takasaka S, Kishimoto K et al. Combination treatment with an alpha1-blocker plus an anticholinergic for the patients with suspected bladder outlet obstruction (BOO) concomitant with over-active bladder (OAB). (Abstract). Proceedings of the International Continence Society 2004; 34th Annual Meeting, with the International UroGynecological Association, Paris, France: Abstract 471
  • 41
    Cucci A, Colli E. Bladder voiding dynamics in BPH patients treated with high dose flavoxate. Proceedings of the International Continence Society 1990; 20th Annual Meeting, Aarhus, Denmark. Abstract 119: 215–6
  • 42
    Gu FL, Reng ZY, Shang GZ et al. Treatment of urgency and urge incontinence with flavoxate in the People’s Republic of China. J Int Med Res 1987; 15: 3128
  • 43
    Fujinaga T. A clinical study of bladderon in BPH patients. Med Consultation New Remedies 1982; 19: 19745
  • 44
    Rokiyo M. A clinical study of Bladderon tablets in patients with benign prostatic hypertrophy. Shinyaku Rinsho 1981; 30: 147880
  • 45
    Niijima M, Ileno A, Kawabe K. A multicenter clinical trial of flavoxate hydrochloride. Nishinihon J Urol 1981; 43: 105563
  • 46
    Yoshida H. Clinical effects of Bladderon tablets against nocturnal pollakiuria in BPH patients. Shinyaku Rinsho 1981; 30: 16179
  • 47
    Ikegami S, Shirai T, Yamada T, Kato H. A clinical study of combined therapy with Eviprostat and Bladderon tablets in BPH patients. Shinyaku Rinsho 1981; 30: 14813
  • 48
    Reynard JM. Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents? Curr Opin Urol 2004; 14: 136
  • 49
    Gonzalez RR, Te AE. Overactive bladder and men: indications for anticholinergics. Curr Urol Rep 2003; 4: 42935
  • 50
    Ruggieri MR Sr, Braverman AS, Pontari MA. Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction. J Urol 2005; 174: 17438
  • 51
    Moher D, Pham B, Lawson ML, Klassen TP. The inclusion of reports of randomised trials published in languages other than English in systematic reviews. Health Technol Assess 2003; 7: 190
  • 52
    Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 2006; 175: 1915
  • 53
    Fowler CJ. Integrated control of lower urinary tract – clinical perspective. Br J Pharmacol 2006; 147 (Suppl. 2): S1424